Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2013 - 2026)

Amphastar Pharmaceuticals' EPS (Basic) history runs 14 years deep, the most recent figure standing at $0.14 for Q1 2026.

• On a quarterly basis, EPS (Basic) fell 73.31% year-over-year to $0.14 in Q1 2026; TTM through Mar 2026 was $2.26, a 24.01% decrease from a year earlier, with the FY2025 full-year figure at $2.59, down 21.53% from the prior year.
• EPS (Basic) eased to $0.14 in Q1 2026 per AMPH's latest filing, from $1.02 in the prior quarter.
• Across five years, EPS (Basic) topped out at $1.02 in Q3 2023 and bottomed at -$3.01 in Q4 2023.
• The 5-year median for EPS (Basic) is $0.56 (2023), against an average of $0.41.
• Across the five-year window, EPS (Basic) soared 522.27% in 2022 and plunged 530.12% in 2023, its largest moves.
• Year by year, EPS (Basic) stood at $0.7 in 2022, then plunged by 530.12% to -$3.01 in 2023, then jumped by 126.05% to $0.78 in 2024, then grew by 29.86% to $1.02 in 2025, then tumbled by 86.08% to $0.14 in 2026.
• Per Business Quant, the three latest AMPH EPS (Basic) figures stand at $0.14 (Q1 2026), $1.02 (Q4 2025), and $0.37 (Q3 2025).